A Phase I Study of SGN-CD19A in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Full Title

A Phase 1, Open-label, Dose-escalation Study of SGN-CD19A in Patients with Relapsed or Refractory B-lineage Non-Hodgkin Lymphoma


The purpose of this study is to identify the highest dose of an investigational drug called SGN-CD19A that can be given safely in patients with non-Hodgkin lymphoma (NHL) that has persisted or returned despite standard therapy. SGN-CD19A has two parts: one (an antibody) that attaches to a protein called CD19 on the surface of cancer cells (including some lymphomas), and another (an anticancer drug called monomethyl auristatin F) that kills the cancer. SGN-CD19A is given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have B-cell NHL that has persisted or returned despite at least one regimen of standard therapy.
  • At least 2 weeks must have passed since completion of prior therapy and entry into the study (12 weeks since monoclonal antibody or radioimmunological therapies).
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is open to patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Craig Moskowitz at 212-639-2696.





Disease Status

Relapsed or Refractory